Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

<i>FLCN</i>-Mutated Tumors in Smith-Magenis Syndrome: A Case Report of <i>FLCN</i>-Associated Pathogenesis.

International journal of surgical pathology·2026
Same author

Mesothelial Lesions of the Testis: A Review.

Advances in anatomic pathology·2026
Same author

Piloleiomyoma and renal cell carcinoma in a 30-year-old woman with hereditary leiomyomatosis and renal cell cancer syndrome.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

A minor high-grade component in non-invasive papillary urothelial carcinoma is not associated with a more indolent behaviour.

Histopathology·2025
Same author

Response to Zheng et al: "Advances and challenges in diagnostic strategies for HLRCC-A Letter to the Editor regarding the study by Ouchene et al on HLRCC".

Journal of the American Academy of Dermatology·2025

Related Experiment Video

Updated: May 25, 2026

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

Immunohistochemical pitfalls in prostate pathology.

Fadi Brimo1, Jonathan I Epstein

  • 1Department of Pathology, McGill University Health Center, Montreal, QC, Canada H3A 2B4.

Human Pathology
|February 14, 2012
PubMed
Summary
This summary is machine-generated.

Diagnosing prostate cancer, especially small tumors, is challenging. Immunohistochemistry, using markers like p63 and 34BE12, is crucial for accurate diagnosis and avoiding misinterpretation of prostate adenocarcinoma.

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry
09:15

Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry

Published on: July 26, 2019

Related Experiment Videos

Last Updated: May 25, 2026

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry
09:15

Optimization, Design and Avoiding Pitfalls in Manual Multiplex Fluorescent Immunohistochemistry

Published on: July 26, 2019

Area of Science:

  • Pathology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate adenocarcinoma diagnosis relies on architectural, cytological, and immunohistochemical features.
  • Early cancer detection presents challenges in diagnosing small foci with few atypical glands.
  • Immunohistochemistry is vital for evaluating these foci and confirming basal cell absence.

Purpose of the Study:

  • To review the utility and limitations of immunohistochemistry in diagnosing prostate adenocarcinoma.
  • To highlight common pitfalls in interpreting immunostains for prostate cancer.
  • To ensure accurate diagnosis and minimize misdiagnoses in challenging cases.

Main Methods:

  • Utilizing basal cell markers such as anti-keratin 34BE12 and p63.
  • Employing α-methylacyl-CoA racemase as a cytoplasmic marker for prostate adenocarcinoma.
  • Confirming prostatic origin of tumors using immunohistochemistry in primary or metastatic settings.

Main Results:

  • Immunohistochemistry is essential for diagnosing small prostate cancer foci by detecting basal cells.
  • Markers like 34BE12, p63, and α-methylacyl-CoA racemase aid in differentiating adenocarcinoma.
  • Immunohistochemistry confirms prostatic origin, distinguishing it from other carcinomas.

Conclusions:

  • Immunohistochemistry is indispensable for accurate prostate adenocarcinoma diagnosis, particularly in challenging biopsy cases.
  • Awareness of marker utility, limitations, and interpretation pitfalls is critical for pathologists.
  • Proper application of immunohistochemistry minimizes misdiagnoses and improves patient outcomes.